纳米囊
细胞内
体内
药物输送
纳米载体
药理学
适体
癌症治疗
癌症研究
材料科学
化学
癌症
医学
纳米技术
分子生物学
生物化学
生物
纳米颗粒
生物技术
内科学
作者
Peiyan Yuan,Fen Yang,Si Si Liew,Jiachang Yan,Xiao Dong,Jinfeng Wang,Shubo Du,Xin Mao,Liqian Gao,Shao Q. Yao
出处
期刊:Biomaterials
[Elsevier]
日期:2022-02-01
卷期号:281: 121376-121376
被引量:17
标识
DOI:10.1016/j.biomaterials.2022.121376
摘要
Combination therapy is a promising strategy for treating multidrug-resistant (MDR) cancers. Macromolecules such as antibodies and RNAs have been successfully used for targeted therapy owing to their high specificity. However, their application as therapeutics remains limited due to membrane impermeability and poor intracellular stability. Designing drug delivery systems capable of co-administering macromolecules is therefore crucial for advancing them as therapeutics for combination therapy. Herein, by using glutathione (GSH)-responsive biodegradable silica nanocapsules (BS-NPs), we report for the first time a highly versatile nanomaterial-based strategy for co-encapsulation and intracellular co-delivery of different combinations of macromolecules (i.e., siRNA/protein, siRNA/antibody and protein/antibody). This strategy was successfully used in the intracellular co-delivery of siRNA/Cetuximab (also named Erbitux™) for combination therapy in epidermal growth factor receptor (EGFR)-overexpressing cancer cells. These BS-NPs showed good biosafety profiles and antitumor efficacy when administered in vivo, suggesting that the strategy holds potential as a novel delivery platform for combination cancer therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI